KR20200059249A - 신경아세포종의 치료를 위한 항-gd2 항체 - Google Patents

신경아세포종의 치료를 위한 항-gd2 항체 Download PDF

Info

Publication number
KR20200059249A
KR20200059249A KR1020207011096A KR20207011096A KR20200059249A KR 20200059249 A KR20200059249 A KR 20200059249A KR 1020207011096 A KR1020207011096 A KR 1020207011096A KR 20207011096 A KR20207011096 A KR 20207011096A KR 20200059249 A KR20200059249 A KR 20200059249A
Authority
KR
South Korea
Prior art keywords
antibody
fragment
iga
ser
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207011096A
Other languages
English (en)
Korean (ko)
Inventor
제네테 헤리카 윌헴미나 레우센
조한네스 제라더스 마리아 에버스
Original Assignee
유엠씨 우트레크트 홀딩 비.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유엠씨 우트레크트 홀딩 비.브이. filed Critical 유엠씨 우트레크트 홀딩 비.브이.
Publication of KR20200059249A publication Critical patent/KR20200059249A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
KR1020207011096A 2017-09-21 2018-09-21 신경아세포종의 치료를 위한 항-gd2 항체 Ceased KR20200059249A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17192476.4 2017-09-21
EP17192476 2017-09-21
PCT/NL2018/050629 WO2019059771A2 (en) 2017-09-21 2018-09-21 ANTI-GD2 ANTIBODIES FOR THE TREATMENT OF NEUROBLASTOMA

Publications (1)

Publication Number Publication Date
KR20200059249A true KR20200059249A (ko) 2020-05-28

Family

ID=59955406

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207011096A Ceased KR20200059249A (ko) 2017-09-21 2018-09-21 신경아세포종의 치료를 위한 항-gd2 항체

Country Status (12)

Country Link
US (2) US11866511B2 (https=)
EP (1) EP3684818A2 (https=)
JP (2) JP2020534370A (https=)
KR (1) KR20200059249A (https=)
CN (1) CN111278862A (https=)
AU (3) AU2018336017B2 (https=)
BR (1) BR112020005742A2 (https=)
CA (1) CA3076482A1 (https=)
IL (1) IL273454A (https=)
MX (1) MX2020003201A (https=)
SG (1) SG11202002581WA (https=)
WO (1) WO2019059771A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114096559B (zh) * 2019-03-27 2026-03-20 蒂嘉特克斯公司 工程化iga抗体及其使用方法
CN111849904B (zh) * 2020-07-31 2021-05-04 浙江科途医学科技有限公司 神经母细胞瘤类器官的培养基、培养方法及移植体
EP4326292A4 (en) * 2021-04-23 2025-03-26 Vivasor, Inc. Dimeric antigen receptors (dars) that bind gd2
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
EP4724490A2 (en) 2023-06-12 2026-04-15 Amgen Inc. Lymphotoxin beta receptor agonist binding proteins
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284536B1 (en) 1998-04-20 2001-09-04 The Regents Of The University Of California Modified immunoglobin molecules and methods for use thereof
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
EP1916257A1 (en) * 2006-10-27 2008-04-30 Charite-Universitätsmedizin Berlin GD2 peptide mimotopes for anticancer vaccination
US8313730B2 (en) 2006-12-13 2012-11-20 Michael R. Simon Treatment of celiac disease with IgA
EP2578681B1 (en) 2010-05-24 2015-07-01 Kagoshima University Iga-binding peptide and iga purification using same
EP2465536A1 (en) 2010-12-14 2012-06-20 CSL Behring AG CD89 activation in therapy
EP2791170A1 (en) 2011-12-16 2014-10-22 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
EP2636681A1 (en) 2012-03-09 2013-09-11 CSL Behring AG Process for enriching IgA
BR112014022240A2 (pt) 2012-03-09 2017-08-01 Csl Behring Ag composições compreendendo imunoglobulinas semelhantes à secretoras
WO2013189516A1 (en) * 2012-06-18 2013-12-27 Apeiron Biologics Ag Method for treating a gd2 positive cancer
CN104736174B (zh) 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
US9890216B2 (en) 2012-10-23 2018-02-13 Board Of Regents, The University Of Texas System Antibodies with engineered IgG Fc domains
CN106414494B (zh) * 2013-11-12 2020-09-18 Ogd2药物 具有促凋亡活性的人IgG1衍生的抗体
ES2768649T3 (es) * 2013-11-21 2020-06-23 Apeiron Biologics Ag Preparaciones para tratar un cáncer positivo para GD2
CN105732814B (zh) * 2016-03-08 2019-05-28 苏州大学 抗人血管性血友病因子a3区的人鼠嵌合单克隆抗体及其制备方法和应用
EP3747438A1 (en) 2017-07-24 2020-12-09 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Treating pathological conditions by direct and indirect targeting of sirpa - cd47 interaction

Also Published As

Publication number Publication date
AU2018336017B2 (en) 2021-06-24
US20210179732A1 (en) 2021-06-17
BR112020005742A2 (pt) 2020-10-13
US20200283541A1 (en) 2020-09-10
CN111278862A (zh) 2020-06-12
JP2020534370A (ja) 2020-11-26
AU2025201363A1 (en) 2025-03-20
EP3684818A2 (en) 2020-07-29
SG11202002581WA (en) 2020-04-29
MX2020003201A (es) 2020-08-13
AU2021236513A1 (en) 2021-10-21
CA3076482A1 (en) 2019-03-28
JP2024023238A (ja) 2024-02-21
WO2019059771A3 (en) 2019-10-10
US11866511B2 (en) 2024-01-09
NZ762835A (en) 2024-12-20
IL273454A (en) 2020-05-31
WO2019059771A2 (en) 2019-03-28
AU2018336017A1 (en) 2020-04-09

Similar Documents

Publication Publication Date Title
US11866511B2 (en) Anti-GD2 antibody
KR101323455B1 (ko) 푸코실 잔기가 결여된 ｃｄ30에 대한 단클론 항체
US11384144B2 (en) T cell receptor-like antibodies specific for a PRAME peptide
CN112566935B (zh) 抗ox40抗体和使用方法
TWI522366B (zh) 與ｃｘｃｒ４結合之人抗體及彼之用途
CN101356195B (zh) 抗岩藻糖基-gm1的人单克隆抗体及使用抗岩藻糖基-gm1抗体的方法
JP2021525082A (ja) 抗ｓｉｒｐａ抗体およびその使用法
US20230235055A1 (en) Monoclonal antibodies against lilrb1 for diagnostic and therapeutic use
CA3000396A1 (en) Antagonistic antibodies specifically binding human cd40 and methods of use
KR20160002864A (ko) 항-cd38 항체 및 감쇠 인터페론 알파-2ｂ와의 융합체
KR20110122859A (ko) Ｃｄ１９에 결합하는 인간화된 항체 및 그것의 용도
JP2021513329A (ja) 抗ｍｓ４ａ４ａ抗体及びその使用方法
JPWO2020004492A1 (ja) Ｃｅｌｌ Ａｄｈｅｓｉｏｎ Ｍｏｌｅｃｕｌｅ３に結合する抗体
KR20070036038A (ko) 아이아르티에이(ｉｒｔａ)-5 항체 및 그의 용도
KR20080099319A (ko) 인간화 항 ｃｄ20 모노클로날 항체
JP2023527583A (ja) Ｌａｇ３に結合する抗体およびその使用
JP2021513328A (ja) 抗ｍｓ４ａ６ａ抗体及びその使用方法
JPWO2020004490A1 (ja) コンドロイチン硫酸プロテオグリカン−５に結合する抗体
US11414495B2 (en) CD20 antibodies
CN101233156A (zh) Cd19抗体及其用途
CN114729051A (zh) 使用抗ox40抗体与放射组合治疗癌症的方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000